Where does current and future pediatric asthma treatment stand? Remodeling and inflammation: Bird’s eye view.

Where does current and future pediatric asthma treatment stand? Remodeling and inflammation: Bird’s eye view.

Pediatr Pulmonol. 2016 May 27;

Authors: Yilmaz O, Yuksel H

Abstract
Airway remodeling is the chronic outcome of inflammation in asthma and a point of intervention between pediatric and adult ages. Pediatric asthma has been of great interest in the efforts to find a valuable time to interrupt remodeling. Various experimental and clinical research have assessed the effect of current therapeutic modalities on airway remodeling in asthma and many new agents are being developed with promising results. The heterogeneity in the results of these studies may lie in the heterogeneity of pathogenesis leading to asthma and remodeling; underlying the need for individualized treatment of the unique pathogenetic characteristics of each child’s asthma. The aim of this review is to summarize the evidence about the influence of current and future therapeutic modalities in the concept of inflammation and remodeling in pediatric asthma. Pediatr Pulmonol. 2016; 9999:1-9. © 2016 Wiley Periodicals, Inc.

PMID: 27233079 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Researchers identify biological pathway that explains why current asthma therapies fail in many cases – News-Medical.net

Researchers identify biological pathway that explains why current asthma therapies fail in many cases
News-Medical.net
Asthma is an enormous public health problem that continues to grow larger, in part because scientists don't fully understand how it is caused. Existing therapies don't cure the disease and often don't even significantly alleviate the symptoms. Now

View full post on asthma – Google News

Current and future biomarkers in allergic asthma.

Related Articles

Current and future biomarkers in allergic asthma.

Allergy. 2015 Dec 25;

Authors: Zissler UM, Bieren JE, Jakwerth CA, Chaker AM, Schmidt-Weber CB

Abstract
Diagnosis early in life, sensitization, asthma endotypes, monitoring of disease and treatment progression are key motivations for the exploration of biomarkers for allergic rhinitis and allergic asthma. The number of genes related to allergic rhinitis and allergic asthma increases steadily, however prognostic genes have not yet entered clinical application. We hypothesize that the combination of multiple genes may generate biomarkers with prognostic potential. The current review attempts to group more than 161 different potential biomarkers involved in respiratory inflammation to pave the way for future classifiers. The potential biomarkers are categorized into either epithelial or infiltrate-derived or mixed origin, epithelial biomarkers. Furthermore surface markers were grouped into cell-type specific categories. The current literature provides multiple biomarkers for potential asthma endotypes that are related to T cell phenotypes such as Th1, Th2, Th9, Th17, Th22 and Tregs and their lead cytokines. Eosinophilic and neutrophilic asthma endotypes are also classified by epithelium-derived CCL-26 and osteopontin, respectively. There are currently about 20 epithelium-derived biomarkers exclusively derived from epithelium, which are likely to innovate biomarker panels as they are easy to sample. This article systematically reviews and categorizes genes and collects current evidence that may promote these biomarkers to become part of allergic rhinitis or allergic asthma classifiers with high prognostic value. This article is protected by copyright. All rights reserved.

PMID: 26706728 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Despite Generic Erosion of Current Market Leaders, the Asthma Market Will … – MarketWatch

Despite Generic Erosion of Current Market Leaders, the Asthma Market Will
MarketWatch
BURLINGTON, Mass., Sept. 22, 2015 /PRNewswire/ — Decision Resources Group finds that the market for asthma will remain relatively flat, increasing slightly from $15.9 billion in 2014 to $16.2 billion in 2024 across the seven major markets (the United

View full post on asthma – Google News

Study: Current treatments are not effective to treat severe asthma – TheHealthSite


Times of India

Study: Current treatments are not effective to treat severe asthma
TheHealthSite
The immune response that occurs in patients with severe asthma is markedly different than what occurs in milder forms of the lung condition, says a new study by an Indian-origin researcher. These unique features could point the way to new treatments.
Severe asthma fails to respond to treatmentTimes of India
Study could point the way to new treatments for people with severe asthmaNews-Medical.net

all 13 news articles »

View full post on asthma – Google News

Asthma Statistics by State: What You Need to Know About Lifetime and Current … – NerdWallet (blog)


NerdWallet (blog)

Asthma Statistics by State: What You Need to Know About Lifetime and Current
NerdWallet (blog)
Asthma is among the leading chronic diseases in the United States, affecting 1 in 12 adults and nearly 1 in 10 children, according to estimates by the Centers for Disease Control and Prevention. It also accounts for billions of dollars in annual costs

View full post on asthma – Google News

Risk factors for current wheezing and its phenotypes among elementary school children.

Risk factors for current wheezing and its phenotypes among elementary school children.

Pediatr Pulmonol. 2011 Feb;46(2):166-174

Authors: Civelek E, Cakir B, Orhan F, Yuksel H, Boz AB, Uner A, Sekerel BE

BACKGROUND: Accumulating evidence suggests, asthma includes many phenotypes with varying clinical and prognostic features. Epidemiological surveys documented a number of environmental risk factors for the development of asthma and interestingly these differ between and within countries, suggesting that the differences may be related with the different distribution of asthma phenotypes. This study aimed to investigate risk factors of current wheezing (CW) and different wheezing phenotypes in elementary school children. METHODS: Six thousand nine hundred sixty-three 9- to 11-year-old children of a previous multicenter survey where the methodology of the International Study of Asthma and Allergies in Childhood (ISAAC) Phase-II was used were analyzed. Wheezing phenotypes were defined as wheezing with rhinitis (RW), wheezing with rhinoconjunctivitis (RCW), atopic wheezing (AW), non-atopic wheezing (NAW), and frequent wheezing (FW) (?4/year wheezing episodes). RESULTS: The prevalence of CW was 15.8% and among these, 22.4%, 67.3%, 45.9%, 20.5%, and 79.5% were classified as FW, RW, RCW, AW, and NAW, respectively. History of parental asthma/allergic rhinitis, coexistence of other allergic diseases, presence of mold and dampness in the house lived during the first year of life and maternal smoking in pregnancy were found to be risk factors for most phenotypes (odds ratio (OR) ranged from 1.43 to 3.56). Number of household in the last year (OR?=?1.14), prematurity (OR?=?2.08), and duration of breastfeeding (OR?=?1.02) per additional month were found to be risk factor for FW, AW, and RCW, respectively. CONCLUSION: Beside common risk factors for the development of asthma and its phenotypes, certain risk factors appeared to play a role in the development of phenotypic characteristics of asthma. These findings support our hypothesis that each phenotype has not only different clinical characteristics but also has different roots. Pediatr. Pulmonol. 2011; 46:166-174. © 2011 Wiley-Liss, Inc.

PMID: 21290615 [PubMed – as supplied by publisher]

View full post on pubmed: asthma